Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.49 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.48 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29639192 | 0.86 | SERPINE1 (0.56) | ALDH1A1KDM4EHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL5534618 | 0.84 | ALDH1A1 (0.47) | NR3C1PGRNR3C2ARALDH1A1 | |
| SCHEMBL3123433 | 0.83 | KMT2A (0.50) | NR3C1PGRNR3C2ARALDH1A1 | |
| SCHEMBL1376795 | 0.82 | ALDH1A1 (0.48) | ALDH1A1KDM4EHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL3117498 | 0.81 | DPP4 (0.53) | ALDH1A1KDM4EHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL3116031 | 0.81 | KCNA5 (0.53) | ALDH1A1KDM4EHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL29773341 | 0.81 | KCNA5 (0.53) | ALDH1A1KDM4EHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL5195360 | 0.81 | KDM4E (0.58) | NR3C1PGRNR3C2ARALDH1A1 | |
| SCHEMBL18019742 | 0.81 | ALDH1A1 (0.57) | NR3C1PGRNR3C2ARALDH1A1 | |
| SCHEMBL25544687 | 0.81 | MAPK13 (0.48) | ALDH1A1KDM4EHPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338449-B2 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-25 | — | — | US | claimed |
| JP-4718467-B2 | — | — | 2011-07-06 | — | — | JP | claimed |
| US-20100256698-A1 | Isoquinolinone Potassium Channel Inhibitors | MERCK & CO., INC. (US) | 2010-10-07 | — | — | US | claimed |
| EP-1667982-A4 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | claimed |
| US-20070027177-A1 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | claimed |
| EP-1667982-A2 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005030791-A2 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | claimed |
| EP-1667982-B1 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-1667982-B1 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8338449-B2 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338449-B2 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338449-B2 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100256698-A1 | Isoquinolinone Potassium Channel Inhibitors | MERCK & CO., INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20070027177-A1 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
| US-20070027177-A1 | Isoquinolinone potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
| US-20060276450-A1 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2006-12-07 | — | — | US | disclosed |
| EP-1667982-A2 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1667979-A2 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030130-A2 | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030791-A2 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276450-A1 | Isoquinoline potassium channel inhibitors | KCNQ1, KCNQ2, KCNJ2 | NR3C1 4823/4885PGR 4776/4885NR3C2 3632/4885 |
| US-20070027177-A1 | Isoquinolinone potassium channel inhibitors | KCNJ2, KCNQ1, KCNQ2 | NR3C1 4750/4885PGR 4727/4885NR3C2 2992/4885 |
| US-20100256698-A1 | Isoquinolinone Potassium Channel Inhibitors | KCNJ2, KCNQ1, KCNQ2 | NR3C1 4811/4885PGR 4771/4885NR3C2 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.